[Featured Stock] JW Jungwoo Pharmaceutical Shows Strength as Roche's 'Actemra' Used to Verify COVID-19 Phase 3 Clinical Treatment Effectiveness
[Asia Economy Reporter Yoo Hyun-seok] JW Pharmaceutical is showing strong performance. It appears that the news of Roche planning to conduct a Phase 3 clinical trial combining the arthritis treatment drug 'Actemra' and Gilead's new drug candidate 'Remdesivir' to verify the treatment effect for the novel coronavirus infection (COVID-19) has influenced this trend.
As of 9:55 AM on the 29th, JW Pharmaceutical was trading at 35,100 KRW, up 5.09% (1,700 KRW) compared to the previous trading day.
According to related industries, Roche conducted a global Phase 3 clinical trial in March to confirm the COVID-19 treatment effect of Actemra. Additionally, a Phase 3 clinical trial combining Remdesivir is also underway. Patient enrollment for this trial will begin next month.
Hot Picks Today
![About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]](https://cwcontent.asiae.co.kr/asiaresize/93/2026051416263163580_1778743590.jpg)
About 100 Trillion Won at Stake... "Samsung Strike Is an Unprecedented Opportunity" as Prices Surge 20% [Taiwan Chip Column]
- "Heading for 2 Million Won": The Company the Securities Industry Says Not to Doubt [Weekend Money]
- "Envious of Korean Daily Life"...Foreign Tourists Line Up in Central Myeongdong from Early Morning [Reportage]
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- Did Samsung and SK hynix Rise Too Much?... Foreign Assets Grow Despite Selling [Weekend Money]
Actemra is an autoimmune disease treatment used for rheumatoid arthritis. Actemra is a drug for which JW Pharmaceutical holds the development and commercialization rights. Recently, it has been highlighted as a treatment for COVID-19.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
